FDA Approves Diovan(R) for Treatment of High Blood Pressure i...(East Hanover New Jersey Novartis Pharmac...)

Date:12/3/2007

East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS), a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.pharma.us.novartis.com.

(1) Sorof J, Lai D, Turner J, et al. Overweight, ethnicity and the

prevalence of hypertension in school-aged children. Pediatrics

2004;113:475-482.

(2) Ford ES, et al. Trends in Risk Factors for Cardiovascular Disease

Among Children and Adolescents in the United States. Pediatrics.

2004;114:1534-1544.

(3) Ogden CL, et al. Prevalence and Trends in Overweight Among US Children

and Adolescents, 1999-2000. JAMA. 2002;288:1728-1732.

(4) Hayman L, Meininger J, Daniels S, et al. Primary Prevention of

Cardiovascular Disease in Nursing Practice: Focus on Children and

'/>"/>

SOURCE Novartis Pharmaceuticals Corporation Copyright©2007 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML